Pulmonary Arterial Hypertension (PAH)

PAH (WHO Group 1) is a progressive disease of the pulmonary vasculature characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance, ultimately leading to right heart failure. Early diagnosis and combination therapy improve survival.

Symptoms

• Exertional dyspnea, fatigue, chest pain
• Syncope or near-syncope
• Palpitations, edema, abdominal distention
• Cyanosis, clubbing (advanced)
• Signs of right heart failure (JVD, hepatomegaly)

Causes (WHO Group 1)

• Idiopathic, heritable (BMPR2 mutations)
• Drug/toxin-induced (methamphetamines, anorexigens)
• Connective tissue disease (scleroderma), HIV, portal hypertension, congenital heart disease, schistosomiasis

Diagnosis

• Transthoracic echocardiogram for screening
• Right heart catheterization (RHC) confirms: mPAP > 20 mmHg, PA wedge pressure ≤ 15 mmHg, PVR ≥ 2 Wood units
• V/Q scan to rule out chronic thromboembolic PH
• Pulmonary function tests, HRCT, lab work (autoimmune, HIV, liver)
• 6-minute walk test (6MWT) or CPET for functional capacity
• BNP/NT-proBNP for prognosis

Risk Stratification

• Functional class (NYHA/WHO I–IV)
• 6MWT distance, cardiopulmonary exercise data
• Echocardiographic parameters, hemodynamics, biomarkers
• Determines treatment intensity and transplant referral timing

Treatment Strategy

Supportive Measures

• Vaccinations (influenza, pneumococcal, COVID-19, RSV)
• Diuretics for right-sided heart failure, optimize iron status
• Oxygen therapy if hypoxemic, avoid high altitude
• Pregnancy avoidance (high maternal mortality)

Targeted Therapies (Goal: low-risk status)

• Endothelin Receptor Antagonists: bosentan, ambrisentan, macitentan
• Phosphodiesterase-5 Inhibitors: sildenafil, tadalafil
• Soluble Guanylate Cyclase Stimulator: riociguat
• Prostacyclin Pathway: epoprostenol (IV), treprostinil (IV/SC/inhaled/oral), iloprost, selexipag
• Combination therapy (dual/triple) is standard upfront in many patients

Advanced Options

• Atrial septostomy or Potts shunt for refractory cases
• Lung or heart-lung transplant
• Clinical trials for novel pathways (TGF-β, BMPR2 signaling)

Lifestyle & Rehabilitation

• Supervised low-intensity exercise/pulmonary rehab
• Sodium restriction to manage fluid retention
• Monitor weight, BP, SpO2 daily
• Manage mental health; PAH is emotionally burdensome

Living with PAH

• Track symptoms, functional class, 6MWT, oxygen needs, BNP values
• Adhere strictly to complex medication regimens; manage infusion pumps/catheters meticulously
• Plan travel with oxygen supply and medication backups
• Maintain close follow-up with specialized PAH center

Complications

• Right heart failure, arrhythmias, sudden death
• Hemoptysis, syncope
• Progressive exercise intolerance, cachexia

Research & Future Directions

Emerging therapies target BMPR2 restoration, anti-proliferative pathways, and metabolic remodeling. Regenerative approaches and precision digital monitoring are under investigation.

Experimental & Emerging Treatments

• BMPR2 Agonists & Gene Editing: Aim to correct signaling defects in heritable PAH.
• Metabolic Modulators (ranolazine, dichloroacetate): Target mitochondrial dysfunction.
• Inhaled Nitric Oxide Delivery Systems: Portable devices for on-demand pulmonary vasodilation.
• Wearable Hemodynamic Sensors: Implantable devices continuously monitor pulmonary pressure to tailor therapy.

Track PAH with Diagnoza.care

Keep a Pulse on Your Pulmonary Pressure – Log medications, infusion pump data, oxygen flow, symptoms, 6MWT distances, labs, imaging, and transplant evaluations; capture side effects; and let the AI companion flag clinical changes that require treatment escalation.

---

Medical Disclaimer: Informational only. Work with a specialized PAH center for diagnostic confirmation, risk stratification, and advanced therapy planning. Sources: European Society of Cardiology/European Respiratory Society, American College of Chest Physicians, Pulmonary Hypertension Association